Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,090 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Accepts healthy volunteers

Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents

NCT03157063
Conditions
Physical Activity, Sedentary Lifestyle, Metabolism, Energy Balance
Interventions
Data Collection Procedures
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 18 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Not applicable Interventional Results available

MetaNeb® Chest X-ray Study

NCT02871258
Conditions
Atelectasis
Interventions
The MetaNeb® System
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Glioma
Interventions
Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra, abemaciclib + temozolomide, Temozolomide, Brain MRI, Brain CT, EKG, Chest X-ray, Biopsy/resection
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
Interventions
Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
413
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 288 more
Conditions
Gastrostomy Tube
Interventions
Percutaneous endoscopic gastrostomy, Radiologically-inserted gastrostomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Large B-cell Lymphoma, DLBCL
Interventions
89Zr-DFO-REGN3767, PET/CT
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Adenocarcinoma
Interventions
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside, Computed Tomography, Laboratory Biomarker Analysis, Positron Emission Tomography
Drug · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Ischemia
Interventions
Angiogram, Medtronic DCB (paclitaxel)/stent, Angiogram, Bard DCB (paclitaxel)/stent
Device
Lead sponsor
Rabih A. Chaer
Other
Eligibility
40 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Recruiting Not applicable Interventional Accepts healthy volunteers

Increasing Lung Cancer Screening Uptake Among Emergency Department Patients

NCT07287085
Conditions
Screening Compliance, Lung Cancer (Diagnosis), Lung Cancer Diagnosis, Lung Cancer
Interventions
Facilitated referral and text messaging, Basic Referral (enhanced control arm)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Conditions
Solid Tumor
Interventions
[18F]FLT-PET/CT
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Questionnaire Administration, Ramucirumab
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
377
States / cities
Little Rock, Arkansas • Anaheim, California • Baldwin Park, California + 287 more
Not listed Not applicable Interventional Accepts healthy volunteers

Palliative Care Health Literacy Education and QOL Compared to Usual Care

NCT06089499
Conditions
COPD
Interventions
Get Palliative Care: four educational learning module videos
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Conditions
Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Pemigatinib, Survey Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 3 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Quantitative Cardiac Parametric Mapping

NCT02855554
Conditions
Cardiomyopathy, Myocarditis, Ischemic Heart Disease
Interventions
Cardiac Magnetic Resonance (CMR) imaging techniques
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Active, not recruiting Phase 2 Interventional Results available

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

NCT03878095
Conditions
Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ceralasertib, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration
Drug · Procedure · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
41
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bridge Therapy, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Ultrasonographic Elastography
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Malignant Neoplasm, Recurrent Plasma Cell Myeloma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Interventions
Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
10
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more
Completed Not applicable Interventional Results available

Multicenter Hologic Tomosynthesis Study

NCT00971087
Conditions
Breast Cancer
Interventions
Hologic Selenia Dimensions Digital Breast Tomosynthesis System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years to 110 Years · Female only
Enrollment
3,521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
22
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 19 more